Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margitta Retz

Showing results (51-60 of 99) with videos related to

Pageof 10
Sort By:
European Urology|August 11, 2014
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre AnalysisKlaus Brasso, Frederik B Thomsen, Andres J Schrader, et al.
BMC Cancer|June 9, 2015
Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patientsMark Thalgott, Brigitte Rack, Matthias Eiber, et al.
Plos One|January 23, 2018
Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapyAnuja Sathe, Géraldine Chalaud, Immanuel Oppolzer, et al.
Oncology|March 14, 2015
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)Günter Niegisch, Margitta Retz, Mark Thalgott, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized DiseaseJulia Slotta-Huspenina, Kristina Schwamborn, Katja Steiger, et al.
Journal of Hematology & Oncology|March 7, 2014
Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancerMark Thalgott, Thomas Horn, Matthias M Heck, et al.
Asian Journal of Urology|February 24, 2022
Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancerChrista Babst, Thomas Amiel, Tobias Maurer, et al.
Future Oncology (London, England)|September 23, 2020
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinomaPeter J Goebell, Philipp Ivanyi, Jens Bedke, et al.
European Urology|August 19, 2017
AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and EnzalutamideAnna Katharina Seitz, Silvia Thoene, Andreas Bietenbeck, et al.
Oncotarget|August 31, 2016
[11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomySarah M Schwarzenböck, Anna Knieling, Michael Souvatzoglou, et al.
Pageof 10

Showing results (51-60 of 99) with videos related to

Sort By:
Pageof 10
European Urology|August 11, 2014
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre AnalysisKlaus Brasso, Frederik B Thomsen, Andres J Schrader, et al.
BMC Cancer|June 9, 2015
Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patientsMark Thalgott, Brigitte Rack, Matthias Eiber, et al.
Plos One|January 23, 2018
Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapyAnuja Sathe, Géraldine Chalaud, Immanuel Oppolzer, et al.
Oncology|March 14, 2015
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)Günter Niegisch, Margitta Retz, Mark Thalgott, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized DiseaseJulia Slotta-Huspenina, Kristina Schwamborn, Katja Steiger, et al.
Journal of Hematology & Oncology|March 7, 2014
Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancerMark Thalgott, Thomas Horn, Matthias M Heck, et al.
Asian Journal of Urology|February 24, 2022
Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancerChrista Babst, Thomas Amiel, Tobias Maurer, et al.
Future Oncology (London, England)|September 23, 2020
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinomaPeter J Goebell, Philipp Ivanyi, Jens Bedke, et al.
European Urology|August 19, 2017
AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and EnzalutamideAnna Katharina Seitz, Silvia Thoene, Andreas Bietenbeck, et al.
Oncotarget|August 31, 2016
[11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomySarah M Schwarzenböck, Anna Knieling, Michael Souvatzoglou, et al.
Pageof 10